

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

1752-0171PUS1 ✓

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/531580
NEWINTERNATIONAL APPLICATION NO.
PCT/JP2003/013416 ✓INTERNATIONAL FILING DATE
21 October 2003 ✓PRIORITY DATE CLAIMED
24 October 2002 ✓

TITLE OF INVENTION AGENT FOR ELEVATING DENDRITIC CELL PRECURSOR LEVEL IN THE BLOOD

APPLICANT(S) FOR DO/EO/US

Kouji MATSUSHIMA; Hiroyuki YONEYAMA; Yuang ZHANG; Shiro KANEKAKI and Teruo AKUTA


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information: PCT/ISA/210; PCT/IB/332; PCT/IB/306; PCT/IB/301; PCT/IB/304; PCT/IB/308; Verification of Translation; Nine (9) Sheets of Formal Drawings and One (1) Sheet of Sequence Listing

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known—see 37 CFR 1.16)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/571580 NEW	PCT/JP2003/013416	1752-0171PUS1
The following fees have been submitted		CALCULATIONS PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic national fee \$300		\$ 300.00
22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100 All other situations \$200		
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100 International Search Report prepared and provided to the Office \$400 All other situations \$500		\$ 200.00
TOTAL OF 21, 22 and 23 =		\$ 1,000.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.		
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number) RATE
56 - 100 =	/50 =	x \$250.00
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		\$
CLAIMS NUMBER FILED NUMBER EXTRA RATE		
Total claims	10-20 =	x \$ 0.00
Independent claims	3-3 =	x \$ 0.00
MULTIPLE DEPENDENT CLAIM(s) (if applicable) YES		+ \$ 360.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1,360.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.		\$
SUBTOTAL =		\$ 1,360.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).		+ \$
TOTAL NATIONAL FEE =		\$ 1,360.00
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ 40.00
TOTAL FEES ENCLOSED =		\$ 1,400.00
		Amount to be refunded: \$
		Amount to be charged: \$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 1,400.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2448. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.</p>		
SEND ALL CORRESPONDENCE TO:		
 SIGNATURE: Gerald M. Murphy, Jr. NAME: _____		
CUSTOMER NUMBER: 02292 April 18, 2005 /smt		
28,977 REGISTRATION NUMBER		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re International Application of

Kouji MATSUSHIMA et al.

International Serial No. : PCT/JP03/13416

International filing date : October 21, 2003

For : AGENT FOR ELEVATING DENDRITIC CELL PRECURSOR LEVEL IN THE
BLOOD

VERIFICATION OF TRANSLATION

Honorable Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir :

I, Katsufumi HIRATA, residing at 20-25, Nishishinagawa 3-chome, Shinagawa-ku, Tokyo, Japan, declare and state :

- (1) that I am able to read and understand well both the Japanese and English languages;
- (2) that I supervised the translation of the above-identified International Application from Japanese to English;
- (3) that the attached English translation is a true and correct translation of the above-identified International Application to the best of my knowledge and belief; and
- (4) that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 USC 1001, and that such false statements may jeopardize the validity of the application or any patent issuing thereon.

Date : March 16, 2005

Katsufumi Hirata
Signature: Katsufumi HIRATA